profit from every $100 of sales.
$0$100
Fulcrum Therapeutics
$3.77+2.45% today
-14.2% in 1 year
1-year low $2.951-year high $7.30
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Fulcrum Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $6.34 million in 2022 to $0 in 2025, with -$74.9 million of profit last year.
SalesProfit
Fulcrum Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Fulcrum Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Fulcrum Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6 | 3 | 80 | 0 | |
| – | – | – | – | |
| -112 | -111 | -20 | -85 | |
| -110 | -108 | -18 | -83 | |
| -110 | -97 | -10 | -75 | |
| -2.44 | -1.59 | -0.16 | -1.18 | |
| – | – | – | – | |
| -1,768.1% | -3,945.2% | -24.8% | – | |
| -1,732.4% | -3,470.1% | -12.2% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 227 | 258 | 261 | 366 |
| Cash | 35 | 26 | 58 | 198 |
| Total debt | 13 | 11 | 9 | 6 |
| Total liabilities | 28 | 23 | 18 | 17 |
| 199 | 235 | 243 | 349 | |
| 45 | 61 | 62 | 63 | |
| -41.7% | -35.5% | -6.2% | -18.8% | |
| -55.2% | -41.4% | -4.0% | -21.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -97 | -91 | -2 | -60 | |
| 2 | 1 | 0 | 0 | |
| -99 | -91 | -2 | -60 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 13 | 15 | 15 | 12 |
Valuation
- –
- –
- –
- 1.6×
- 3.6×
- –
- –
- -0.9%
- -3.4%
- 0.0%
Profitability
- 0.0%
- -24.8%
- -12.2%
- 0.0%
- -25.5%
- -30.9%
- -27.8%
- -21.9%
- -25.7%
- –
Growth
- +255.2%
- –
- −2,319.0%
- –
- +15.7%
Financial health
- -2.7×
- 0.02
- 1.7%
- –
- 34.33
- 34.33
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 946
Bottom 11%of 872
Top 1%of 867
Bottom 35%of 986
What analysts expect
- Average price target
- $20.67
- Range
- $10.00 – $25.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 27, 2026 | -0.25 | -0.31 | +19.4% |
| Feb 24, 2026 | -0.31 | -0.31 | +0.0% |
| Oct 29, 2025 | -0.31 | -0.29 | −6.9% |
| Jul 29, 2025 | -0.28 | -0.29 | +3.4% |
| May 1, 2025 | -0.28 | -0.29 | +3.4% |
| Feb 25, 2025 | -0.31 | -0.28 | −10.7% |
| Nov 13, 2024 | -0.35 | -0.40 | +12.5% |
| Jul 31, 2024 | 0.87 | 0.01 | +7,060.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
59No pass
Philip Fisher
33No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Fulcrum Therapeutics
Is Fulcrum Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fulcrum Therapeutics AI analysis
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. It is in Biotechnology.
Does Fulcrum Therapeutics pay a dividend?
No. Fulcrum Therapeutics does not pay a dividend at the moment.
Is Fulcrum Therapeutics stock halal?
No. Fulcrum Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 70% of its market value, at or above the 33% limit. How we check
How has Fulcrum Therapeutics stock done over the past year?
Down 14.2% over the past twelve months, to $3.77. It traded between $2.95 and $7.30 and is 48.4% below its high.
Who are Fulcrum Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Fulcrum Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.